About: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data
Creator	Woolhouse, Mark Sheikh, Aziz Gunson, Rory Morrice, Lynn Mcmenamin, Jim Stagg, Helen Robertson, Chris Simpson, Colin Kelly, Dave Marques, Diogo Murray, Josie Ritchie, Lewis Vasileiou, Eleftheria
Source	Medline; PMC
abstract	INTRODUCTION: Following the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 and the ensuing COVID-19 pandemic, population-level surveillance and rapid assessment of the effectiveness of existing or new therapeutic or preventive interventions are required to ensure that interventions are targeted to those at highest risk of serious illness or death from COVID-19. We aim to repurpose and expand an existing pandemic reporting platform to determine the attack rate of SARS-CoV-2, the uptake and effectiveness of any new pandemic vaccine (once available) and any protective effect conferred by existing or new antimicrobial drugs and other therapies. METHODS AND ANALYSIS: A prospective observational cohort will be used to monitor daily/weekly the progress of the COVID-19 epidemic and to evaluate the effectiveness of therapeutic interventions in approximately 5.4 million individuals registered in general practices across Scotland. A national linked dataset of patient-level primary care data, out-of-hours, hospitalisation, mortality and laboratory data will be assembled. The primary outcomes will measure association between: (A) laboratory confirmed SARS-CoV-2 infection, morbidity and mortality, and demographic, socioeconomic and clinical population characteristics; and (B) healthcare burden of COVID-19 and demographic, socioeconomic and clinical population characteristics. The secondary outcomes will estimate: (A) the uptake (for vaccines only); (B) effectiveness; and (C) safety of new or existing therapies, vaccines and antimicrobials against SARS-CoV-2 infection. The association between population characteristics and primary outcomes will be assessed via multivariate logistic regression models. The effectiveness of therapies, vaccines and antimicrobials will be assessed from time-dependent Cox models or Poisson regression models. Self-controlled study designs will be explored to estimate the risk of therapeutic and prophylactic-related adverse events. ETHICS AND DISSEMINATION: We obtained approval from the National Research Ethics Service Committee, Southeast Scotland 02. The study findings will be presented at international conferences and published in peer-reviewed journals.
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1136/bmjopen-2020-039097
bibo:pmid	32565483
has license	cc-by
sha1sum (hex)	075e3a9a2a7039b9c56e6e72f38e259704194557
schema:url	https://doi.org/10.1136/bmjopen-2020-039097
resource representing a document's title	Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data
has PubMed Central identifier	PMC7311023
has PubMed identifier	32565483
schema:publication	BMJ Open
resource representing a document's body	covid:075e3a9a2a7039b9c56e6e72f38e259704194557#body_text
is schema:about of	named entity 'morbidity' named entity 'World Health Organisation' named entity 'population characteristics' named entity 'SARS-CoV' named entity 'patient record' named entity 'change over time' named entity 'Scotland' named entity 'general practices' named entity 'vaccine' named entity 'vaccine' named entity 'SARS-CoV-2' named entity 'intensive care units' named entity 'virus' named entity 'explanatory variable' named entity 'binary variable' named entity 'confounders' named entity 'body mass index' named entity 'COVID' named entity 'demographic' named entity 'coronavirus' named entity 'primary care' named entity 'global population' named entity 'respiratory tract' named entity 'multimorbidity' named entity 'underlying condition' named entity 'infection' named entity 'Epidemiology' named entity 'spleen' named entity 'SES' named entity 'infection' named entity 'attack rate' named entity 'risk group' named entity 'SARS-CoV-2' named entity 'medical conditions' named entity 'H3N2' named entity 'Power calculations' named entity 'A&E' named entity 'SARS-CoV-2' named entity 'NHS' named entity 'secondary bacterial infections' named entity 'antiviral' named entity 'Wuhan' named entity 'Anti-Viral' named entity 'data quality assessment' named entity 'controlled study' named entity 'Mexico' named entity 'influenza viruses' named entity 'COVID-19 disease' named entity 'change over time' named entity 'serology test' named entity 'Scotland' named entity 'prophylactic' named entity 'serology' named entity 'global health' named entity 'COVID' named entity 'morbidity' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'older people' named entity 'reverse transcriptase PCR' named entity 'coronavirus' named entity 'demographic' named entity 'vaccine' named entity 'mortality rate' named entity 'population characteristics' named entity 'infection' named entity 'logistic regression' named entity 'Scotland' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software